Article Data

  • Views 382
  • Dowloads 117

Original Research

Open Access

Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report)

  • A. Wojciechowska-Lacka1
  • J. Markowska2,*,
  • E. Skasko3
  • A. Kruczek3
  • J. Steffen4

1Genetic Counselling Unit, Great Poland Cancer Center, Poznan

2Division of Gynecological Oncology, Department of Oncology, Medical School, Poznan

3Department of Endocrinology, Poland

4Department of Immunology, M. Skiodowska-Curie Memorial Cancer Center and Institute of Oncology, Warszawa, Poland

DOI: 10.12892/ejgo20030121 Vol.24,Issue 1,January 2003 pp.21-24

Published: 10 January 2003

*Corresponding Author(s): J. Markowska E-mail:

Abstract

Purpose: To evaluate frequencies of early disease progressions and recurrences in patients with familial vs sporadic ovarian cancers following primary paclitaxel/cis- or carboplatin chemotherapy.

Methods: The frequencies of disease progression up to six months following primary paclitaxel/cis- or carboplatin and of early disease recurrences were analysed in 18 Stage III patients with familial ovarian cancers, both carriers and non-carriers of 5382 insC BRCA1 mutation, and in 35 patients with Stage III sporadic ovarian tumors.

Results: Progressive disease within first six months following chemotherapy developed in 5/18 patients with familial cancers vs. 5/35 patients with sporadic tumors. Early disease recurrences (up to 6 months after treatment) occurred in 3/18 patients with familial vs. 2/35 patients with sporadic tumors. Recurrences after 7-12 months following treatment occurred, respectively, in 3/13 and 3/31 patients from these groups.

Conclusion: The results of this preliminary report may suggest that patients with familial ovarian tumors respond less favourably to paclitaxel/cis- or carboplatin treatment than patients with sporadic ovarian tumors. These findings should be however confirmed in a prospective study on a larger group of patients.

Keywords

Familial ovarian cancer; BRCAJ mutations; Primary treatment failures; Paclitaxel/platin

Cite and Share

A. Wojciechowska-Lacka,J. Markowska,E. Skasko,A. Kruczek,J. Steffen. Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report). European Journal of Gynaecological Oncology. 2003. 24(1);21-24.

References

[1] Claus E. B., Schildkraut J. M., T hompson W. D. et al.: "The genetic attributable risk of breast and ovarian cancer". Cancer, 1996, 77, 2318.

[2] Lichtenstein P., Holm N. V., Verkasalo P. D. et al.: "Environmental and heritable factors in the causation of cancer. Analysis of cohorts of twins from Sweden, Denmark, and Finland". N Eng. J. Med., 2000, 343, 78.

[3] Rubin S. C., Benjamin I., Behbakht K. et al.: "Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA l". N Engl. J. Med., 1996, 335, 1413.

[4] Aida H., Takakuwa K., Nagata H. et al.: "Clinical features of ovarian cancer in Japanise women with germ-line mutations of BRCA l". Clin. Cancer Res., 1998, 4, 235.

[5] Pharoah P. D. P., Easton D. F, Stockton D. L. et al.: "Survival Ill familial, BRCA 1- associated, and BRCA 2- associated epithelial ovarian cancer". Cancer Res., 1999, 59, 868.

[6] Boyd J., Sonoda Y., Federici M. G. et al.: "Clinicopathologic features of BRCA - linked and sporadic ovarian cancer". J. Amer. Med. Assoc., 2000, 283, 2260.

[7] Ben David Y., Chetrit A., Hirsh-Yechezkel G. et al.: "Effect of BRCA mutations on the length of survival in epithelial ovarian tumors". J. Clin. Oneal., 2002, 20, 463.

[8] Buller R. E., Anderson B., Connor J. P., Robinson R.: "Familial ovarian cancer". Gynecol. Oneal., 1993, 4, 160.

[9] Cannistra S. A. : "BRCAJ mutations and survival in women with ovarian cancer" (letter). N Engl. J. Med., 1997, 336, 1254.

[10] Whitmore S. E.: "BRCAJ mutations and survival in women with ovarian cancer" (letter). N Engl. J. Med., 1997, 336, 1254.

[11] Modan B.: "BRCAJ mutations and survival in women with ovarian cancer" (letter). N Engl. J. Med., 1997, 336, 1255.

[12] Johannsson 0. T., Ranstam J., Borg A., Olsson H.: "BRCAJ mutations and survival in women with ovarian cancer" (letter). N Engl. J. Med., 1997, 336, 1255.

[13] Brunet J.-S., Narod S. A., Tonin P., Foulkes W. D.: "BRCAJ mutations and survival in women with ovarian cancer" (letter). N. Engl. J. Med., 1997, 336, 1256.

[14] Johannsson O. T., Ranstam J., Borg A. et al.: "Survival of BRCAI breast and ovarian cancer patients: a population-based study from southern Sweden". J. Clin. Oneal., 1998, 16, 397.

[15] Scully R. et al.: "Association of BRCAJ with Rad51 in mitotic and meiotic cells". Cell, 1997, 88, 265.

[16] Sharan S. K., Morimatsu M., Albrecht U. et al.: "Embryonic lethality and radiation hypersens巾vity mediated by Rad 51 in mice lacking Brea 2". Nature, 1997, 386, 804.

[17] Chabner B. A., Meyers C. E.: "Clinical pharmacology of cancer chemotherapy". In: "Cancer: Principles and Practice of Oncology". De Vita V.T. jr., Hellman S. and Rosenberg S.A. (eds.). Philadelphia, J. B. Lippincott, 1989, 349.

[18] Rowinsky E. K., Onetto N., Canetta R. et al.: "Taxol: The first of three taxans, an important new class of antitumor agents". Sem. Oneal., 1992, 19, 646.

[19] Calvert A. H., Newel D. R., Gumbrell L. A. et al.: "Carboplatm dosage: Prospective evaluation of a simple formula based on renal function". J. Clin. Oneal., 1989, 7, 1748.

[20] Davelaar E. M., Bonfrer J. M. G., Verstraeten R. A. et al.: "CAl25: A valid marker in ovarian carcionoma patients treated with paclitaxel?". Cancer, 1996, 78. 118.

[21] Gordon J. S., Rustin B., Marples M. et al.: "Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels". J. Clin. Oneal., 2001, 19, 4054.

[22] Sambrook F., Fritsch E. F., Maniatis T.: "Molecular Cloninig. A Laboratory Manual". Cold Spring Harbor, Cold Spring Harbor Laboratory, 1989. Book 2: "Isolation of high-molecular weight DNA from mammalian cells", 9.16.

[23] Paszko Z., Skasko E., Wireniewska A. et al.: "Changes in BRCAI gene in patients with familial breast cancer in the Warsaw region of Poland". Nowotwory J. Oneal., 2002, 52, 97.

[24] Friedman L. S., Ostermeyer E. A., Szabo C. I. et al.: "Confirmation of BRCAI by analysis of germline mutations linked to breast and ovarian cancer in ten families". Nature Genet., 1994, 8, 399.

[25] Couch F. J. and Hartmann L. C.: "BRCAJ testing: advances and retreats". J. Amer. Med. Assoc., 1998, 279, 955.

[26] Grzybowska E., Zientek H., Jasiriska A. et. al.: "High frequency of recurrent mutations in BRCAI and BRCA2 in Polish families with breast and ovarian cancer". Hum. Muta/., 2000, 16, 482.

[27] Gorski B., Byrski T., Hazurski T. et al.: "Founder mutations in the BRCAI gene in Polish families with breast-ovarian cancer". Am. J. Hum. Genet., 2000, 66, 1963.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top